文献速递胃肠动力与功能性疾病

licensed药物在肠易激综合征伴便秘或腹泻试验中的安慰剂反应率:荟萃分析

Placebo Response Rates in Trials of Licensed Drugs for Irritable Bowel Syndrome With Constipation or Diarrhea: Meta-analysis.
PubMed 文献 · Clin Gastroenterol Hepatol · 2021-08-20

该系统综述与荟萃分析纳入17项伴便秘和17项伴腹泻的成人肠易激综合征随机对照试验,评估licensed药物对比安慰剂的反应率。按FDA标准,伴便秘的复合、腹痛和排便安慰剂反应率分别为18.9%、34.6%和30.1%,伴腹泻分别为16.2%、40.2%和16.2%。提高腹痛反应阈值可降低安慰剂反应率。

要点

  • FDA推荐的复合终点安慰剂反应率较低,伴便秘为18.9%,伴腹泻为16.2%。
  • 腹痛终点安慰剂反应率较高,伴便秘为34.6%,伴腹泻为40.2%。
  • 提高腹痛改善阈值至≥40%或≥50%可降低安慰剂反应率。

核心结论

  • 未来随机对照试验应遵循当前FDA推荐的肠易激综合征终点,因其可降低安慰剂反应率。
  • 可考虑进一步优化部分终点以更好区分活性药物与安慰剂。

研究设计与样本

  • 系统综述与荟萃分析,检索MEDLINE、EMBASE和Cochrane对照试验中心注册库至2021年1月。
  • 纳入比较licensed药物与安慰剂的成人肠易激综合征随机对照试验,至少评估复合、腹痛或排便反应之一。
  • 共纳入17项伴便秘试验(安慰剂4603例)和17项伴腹泻试验(安慰剂3908例)。
  • 数据按意向性分析提取,脱落视为治疗失败,采用随机效应模型合并。

主要发现

  • 伴便秘试验中,按FDA标准,12周中≥6周复合、腹痛和排便安慰剂反应率分别为18.9%、34.6%和30.1%。
  • 伴便秘试验中,12周中≥9周复合、腹痛和排便安慰剂反应率分别为4.3%、24.5%和7.7%。
  • 伴腹泻试验中,按FDA标准,复合、腹痛和排便安慰剂反应率分别为16.2%、40.2%和16.2%。
  • 腹痛反应阈值从≥30%提高至≥40%或≥50%时,安慰剂反应率分别为34.5%和23.4%。

关键数值与推荐

  • FDA推荐的复合终点:伴便秘安慰剂反应率18.9%(≥6/12周),伴腹泻16.2%。
  • FDA推荐的腹痛终点:伴便秘安慰剂反应率34.6%(≥6/12周),伴腹泻40.2%。
  • FDA推荐的排便终点:伴便秘安慰剂反应率30.1%(≥6/12周),伴腹泻16.2%。
  • 更严格时间阈值(≥9/12周)下,伴便秘复合终点安慰剂反应率4.3%,腹痛24.5%,排便7.7%。
  • 腹痛改善阈值提高至≥40%或≥50%时,安慰剂反应率分别为34.5%和23.4%。

临床怎么用

  • 解读肠易激综合征临床试验时需考虑终点定义对安慰剂反应率的影响。
  • 采用FDA推荐终点可能降低安慰剂反应率,有利于试验效率。
  • 腹痛终点安慰剂反应率较高,可能需要更严格阈值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: There are several licensed drugs for irritable bowel syndrome (IBS) that have proven efficacy in randomized controlled trials (RCTs), but placebo response rates are high. We conducted a systematic review and meta-analysis of licensed drugs to estimate magnitude of placebo response rate according to Food and Drug Administration (FDA)-recommended endpoints and to assess how this varies with stringency of the endpoint used to define response. METHODS: We searched MEDLINE, EMBASE CLASSIC and EMBASE, and the Cochrane central register of controlled trials (through January 2021) to identify RCTs comparing licensed drugs with placebo in adult IBS patients. Studies assessed efficacy according to at least one of composite response, abdominal pain response, or stool response. Data were extracted as intention-to-treat analyses, with dropouts assumed to be treatment failures and pooled using a random-effects model. RESULTS: There were 17 RCTs of licensed drugs versus placebo in IBS with constipation (4603 patients placebo) and 17 trials in IBS with diarrhea (3908 patients placebo). In IBS with constipation, according to FDA criteria, pooled composite, abdominal pain, and stool response rates with placebo over ≥6 of 12 weeks were 18.9%, 34.6%, and 30.1%, respectively. Evaluating response rates over ≥9 of 12 weeks led to placebo response rates of 4.3% for the composite endpoint, 24.5% for abdominal pain, and 7.7% for stool. In IBS with diarrhea, pooled placebo response rates according to FDA criteria were 16.2% for the composite endpoint, 40.2% for abdominal pain, and 16.2% for stool. Increasing the threshold used to define abdominal pain response from ≥30% improvement to ≥40% or ≥50% led to lower placebo response rates of 34.5% and 23.4%. CONCLUSIONS: Future RCTs should adhere to current FDA-recommended endpoints for IBS because these lead to lower placebo response rates. However, consideration should be given to further refining some of these to better differentiate between active drug and placebo.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Barberio B, Savarino EV, Black CJ, et al. Placebo Response Rates in Trials of Licensed Drugs for Irritable Bowel Syndrome With Constipation or Diarrhea: Meta-analysis. Clin Gastroenterol Hepatol. 2021. PMID: 34425274. doi:10.1016/j.cgh.2021.08.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。